Meeting
2021 ASCO Annual Meeting
A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.
Authors
Xuan Wang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
Xuan Wang , Chuanliang Cui , Lu Si , Caili Li , Jie Dai , Lili Mao , Xue Bai , Zhihong Chi , Xinan Sheng , Yan Kong , BIN LIAN , Bixia Tang , Xieqiao Yan , Li Zhou , Siming Li , Robert H.I. Andtbacka , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04197882
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9570)
DOI
10.1200/JCO.2021.39.15_suppl.9570
Abstract #
9570
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
First Author: Lisanne P. Zijlker
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt
Poster
2023 ASCO Annual Meeting
NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
First Author: Lili Mao
Poster
2023 ASCO Annual Meeting
Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.
First Author: Lili Mao